Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe most common side effects of semaglutide for weight loss are gastrointestinal: nausea, diarrhoea, constipation, vomiting and indigestion. These affect a significant proportion of people who use Wegovy, particularly in the first weeks of treatment or after a dose increase, and they generally ease as the body adjusts. Semaglutide (sold as Wegovy in the UK) is a prescription-only medicine, and a prescriber will discuss your individual suitability and any personal risk factors before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Nausea is the one that comes up most often, and it is real. In the STEP 1 trial, published in the New England Journal of Medicine, gastrointestinal symptoms were the leading reason people reduced or paused their dose. But the pattern matters: side effects of Wegovy for weight loss are heaviest at the start and after each upward step in dose, then tend to taper off as the body acclimates. Many people find that by the time they reach their maintenance dose, the early nausea has largely gone.
The full list from clinical data and the NHS medicines page includes nausea, vomiting, diarrhoea, constipation, stomach pain, indigestion, burping and reflux. Fatigue, headache and dizziness appear less often. Injection-site reactions (mild redness or bruising at the abdomen, thigh or upper arm) are common and usually minor. The NHS semaglutide patient page lists these in full alongside practical guidance on what to do if they become difficult to manage.
A few things help in practice. Eating slowly, choosing smaller portions and avoiding very fatty meals all reduce the chance that nausea tips into vomiting. Staying well hydrated matters too, especially if diarrhoea is persistent. Some people find keeping their pen in the fridge door and injecting just after a light evening meal (so any queasiness happens overnight) makes the first weeks noticeably easier. That said, these are general tips; your prescriber is the right person to adjust your plan if side effects of taking Wegovy for weight loss are interfering with daily life.
Not meaningfully at the same dose. Both contain semaglutide; the active molecule is identical. The difference is the licensed indication and the dosing ceiling. Wegovy titrates up to 2.4 mg weekly for weight management, and the higher maintenance dose does mean a somewhat higher chance of GI symptoms compared with the lower doses used in diabetes treatment. The side effect of Wegovy for weight loss that most distinguishes it from lower-dose use is that sustained appetite suppression (which is the therapeutic goal) can occasionally lead to under-eating, so protein and hydration deserve deliberate attention throughout treatment.
There is also a question our prescribers hear regularly: does adding B12 change anything? Some services combine semaglutide with B12 supplementation. If you want to understand what that involves and any associated considerations, the side effects of semaglutide with B12 for weight loss page covers this in detail. The short answer is that B12 itself has a very low side-effect burden, but the combination is worth discussing with your prescriber.
For a broader look at Wegovy side effects across all indications, including the cardiovascular indication, the dedicated page on our site goes further than this spoke can.
Most people on semaglutide tolerate it well, but there are symptoms that should not be left until the next routine check-in. Seek help promptly if you notice any of the following.
Severe abdominal pain that is persistent, possibly spreading to the back, with or without vomiting, can indicate acute pancreatitis. The MHRA's Drug Safety Update from January 2026 named this as a known but infrequent risk with GLP-1 medicines; it can be serious and needs urgent assessment. Stop taking semaglutide and go to A&E or call 111 if this pattern fits.
Gallbladder symptoms (pain in the upper-right abdomen, fever, yellowing of the skin or eyes) are another reason to seek same-day medical advice. Rapid weight loss itself can raise gallstone risk, and GLP-1 medicines appear to add a modest additional contribution.
Signs of a serious allergic reaction (rash, swelling of the face or throat, difficulty breathing) require a 999 call. Persistent vomiting or diarrhoea leading to dehydration (dark urine, dizziness on standing, inability to keep fluids down) also warrants urgent care, particularly in people with any kidney vulnerability.
If you experience new or worsening low mood or any thoughts of self-harm, contact your GP or call 111. This is listed in the prescribing information and should never be dismissed. You can report any suspected reaction, including unexpected ones, to the MHRA at yellowcard.mhra.gov.uk. Reports from patients shape future safety guidance and are genuinely useful.
The honest answer is that the long-term picture is still building. The STEP programme followed participants for 68 weeks, and real-world data from broader use is accumulating quickly. What the current evidence shows is a favourable cardiovascular signal in people with established heart disease (semaglutide is now separately licensed in the UK for reducing major cardiovascular event risk) which adds to the overall safety picture. For weight management specifically, if you want to understand what the side effects of Wegovy for weight loss look like over time, including what is and is not yet known, the long-term side effects of Wegovy page draws together the current evidence.
NICE's recommendation for semaglutide (TA875) covers use for a maximum of two years within a specialist weight management service; that time limit reflects both the current evidence base and the intention that treatment supports lasting lifestyle change rather than replacing it. Whether continuing beyond that is appropriate is a clinical conversation, not a self-managed decision.
At nume, our prescribers review every repeat order before it is dispensed, there is no auto-renewal. If you have questions about whether Wegovy suits your situation, the consultation is the place to raise them. You can check your eligibility and start that conversation at no cost.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.